DecipHER Trial – DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

DecipHER Trial – DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Conditions:   Triple Negative Breast Cancer;   HER2-negative Breast Cancer
Interventions:   Biological: HER2 – primed Dendritic cells;   Biological: HER3 – primed Dendritic cells
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   The Shulas’ Foundation
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 18, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments